Citadel Advisors
NVIV

Citadel Advisors’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Citadel Advisors’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Hold
0
– -$40K – 9510
2015
Q3 		– Hold
0
– – – 7738
2015
Q2 		– Hold
0
– – – 8071

Other funds holding NVIV

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Citadel Advisors's NVIV Position: Q4 2022 in Review

Citadel Advisors sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q4 2022, closing a stake of 42,794 shares — an estimated $184K sold.

Citadel Advisors first reported a position in NVIV in Q1 2019 and held it in 6 quarters. The position peaked at $184K in Q3 2022. 18 funds tracked by Wall St. Rank hold NVIV as of Q4 2022.

  • Citadel Advisors reported no remaining InVivo Therapeutics Holdings Corp position as of Q4 2022 after selling out during the quarter.
  • Citadel Advisors sold 42,794 InVivo Therapeutics Holdings Corp shares in Q4 2022, an estimated $184K.
  • Citadel Advisors first reported a position in InVivo Therapeutics Holdings Corp in Q1 2019 and held it in 6 quarters.
  • Citadel Advisors's InVivo Therapeutics Holdings Corp position peaked at $184K in Q3 2022.
  • 18 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.